Source comparison
Melanotan-2 Sexual Dysfunction: Mechanism Comparison
Melanotan-2 sexual dysfunction treatment differs fundamentally from other sexual enhancement compounds in both mechanism and clinical application. This table compares melanocortin agonism to PDE5 inhibitors, dopamine agonists, and testosterone replacement to c
This comparison does not assign a generated winner or score.
- Melanotan-2 sexual dysfunction treatment differs fundamentally from other sexual enhancement compounds in both mechanism and clinical application. This table compares melanocortin agonism to PDE5 inhibitors, dopamine agonists, and testosterone replacement to clarify when each mechanism is appropriate.
- Melanotan-2 (Melanocortin Agonist)
- MC4R agonism in hypothalamus → oxytocin/dopamine release → central arousal
- 2–6 hours
- No. Generates spontaneous arousal centrally
- Hypoactive desire disorder, psychogenic ED, arousal-phase dysfunction in both sexes
- Most effective for central desire deficits but significant nausea side effect burden limits clinical use
- PDE5 Inhibitors (Sildenafil, Tadalafil)
- Inhibit cGMP degradation in penile smooth muscle → prolonged nitric oxide-mediated vasodilation
- 30–60 minutes
- Yes. Amplifies existing arousal signals
- Organic erectile dysfunction, vascular insufficiency, performance anxiety in men only
- First-line for male ED but ineffective for desire-phase disorders; does nothing for women
- Dopamine Agonists (Cabergoline, Pramipexole)
- D2 receptor agonism in mesolimbic pathway → increased libido and reward sensitivity
- Days to weeks (chronic dosing)
- No. Increases baseline libido
- Hyperprolactinemia-induced sexual dysfunction, SSRI-associated anorgasmia
- Effective for prolactin-mediated suppression but poor side effect profile (impulse control disorders)
- Testosterone Replacement
- Androgen receptor activation → increased nitric oxide synthase, mood, energy, and libido
- 2–4 weeks (steady-state)
- No. Normalizes baseline function
- Hypogonadism (total T < 300 ng/dL), androgen deficiency in aging males
- Corrects hormone-driven dysfunction but ineffective if testosterone is already normal
- Melanotan-2 fills a niche: central arousal disorders where libido is absent and PDE5 inhibitors fail because the deficit isn't vascular. Bremelanotide's FDA approval for female HSDD validates this niche clinically.